For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients,” says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine.
Archive | Conferences
Blocking tumor signals can hinder cancer’s spread
Posted in Melanoma News, Health Professionals, Conferences
Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma
Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.
Posted in Melanoma News, Health Professionals, Conferences
Blocking tumor signals can hinder cancer’s spread
For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients,” says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine. “Yet there are not many, if any, drugs that specifically target metastatic processes.”
Posted in Melanoma News, Health Professionals, Conferences
Long-Term Biologic Use May Not Raise Melanoma Risk
NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis.
Posted in Melanoma News, Health Professionals, Conferences
